Psoriasis

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.

In this Healio exclusive video, Lawrence F. Eichenfield, MD, talks about takeaways in updates on topical treatments for pediatric and adolescent psoriasis discussed at Maui Derm 2025.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

Scalp psoriasis improvement was maintained with long-term tildrakizumab treatment in what researchers said is the first “dedicated trial” to demonstrate sustainable efficacy of an anti-interleukin-23 inhibitor for the condition.

Pregnant patients with psoriasis hospitalized for delivery have a higher risk for preeclampsia, cardiac arrhythmias and other cardiovascular complications, according to a study.

Published results showed “Latine” patients with psoriasis in the U.S. have unique experiences with their disease and subsequent care, including lack of awareness about psoriasis, workplace difficulties and a preference for biologic treatment.

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, according to a poster presented at Maui Derm Hawaii 2025.

AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque psoriasis, Artax Biopharma announced in a press release.

QX004N, an interleukin-23 inhibitor, showed safety and efficacy in the treatment of moderate to severe plaque psoriasis, according to a study.

The VISIBLE trial demonstrated that intentional efforts to recruit and retain patients with skin of color result in a speedy enrollment process and diverse patient pool, according to a study.